The World Market for Flow Cytometry in IVD Applications
|出版日||ページ情報||英文 40 Pages
|IVD（体外診断）アプリケーションにおけるフローサイトメトリーの世界市場 The World Market for Flow Cytometry in IVD Applications|
|出版日: 2014年06月16日||ページ情報: 英文 40 Pages||
Flow cytometers are powerful reference lab instruments that are now an important component of advanced IVD labs in developed nations. They are advanced diagnostic instruments for cancer diagnostics, but their newer clinical applications included the commercialization and refinement of HIV testing and monitoring through CD4/CD8 counts. Until recently flow cytometry has been used exclusively for these purposes. Other applications are seeing procedure growth.
This report, The World Market for Flow Cytometry in In Vitro Diagnostic Applications, is Kalorama's complete market analysis of this important diagnostics segment.
Flow cytometry is useful in biotechnology, drug development, and clinical research. This report focuses only on IVD applications for flow. As part of its analysis, Kalorama considers growth drivers for the flow cytometry market in diagnostics, examines competitive moves by companies in the market, and reimbursment trends that will affect growth long-term. Profiled manufacturers include:
Kalorama Sees Static Competition in Flow Cytometry Despite New Entrants.
For years, the flow cytometry market has been a battle between Becton Dickinson and Beckman Coulter. And despite the entry of Sysmex and Sony Technology into the market, Kalorama Information doesn't expect that to change. These two terms should fight primarily for the $1,115. The finding was made in the firm's latest market research report. The World Market for Flow Cytometry.
“The two main firms hold 90% plus of the market,” said Bruce Carlson, Publisher of Kalorama Information. “As both the major firms continue to grow by innovation and acquisition, it is not likely that a firm will challenge significant market share of the two largest players in the short term.”
The report presents Kalorama's estimation of the market share for flow cytometry. Two main competitors dominate the market for these systems. BD is the clear leader of the flow cytometry market. BD continues to update its systems and test kits to maintain complete dominance of this market. Beckman Coulter is estimated to have a 22% share of the market. Beckman has made strategic acquisitions to be sure they are on the cutting edge of cytometry.
In recent years, some new competitors entered the market. EMD Millipore, owned by Merck, and Sony technologies, operating through iCyt subsidiary, have developed reputable cytometers. Most recently, Görlitz-based biotechnology and diagnostics company Partec GmbH signed up with Sysmex Corporation based in Kobe, Japan. Partec products will now be distributed worldwide under the Sysmex umbrella. Sysmex is a leading international supplier of in vitro diagnostic products, with annual sales in excess of 1.2 billion euros. Where Partec was previously active in 140 countries, it now has access to a distribution network for 60 additional countries.. Partecs HIV/AIDS, tuberculosis and malaria diagnostic products for emerging countries could see better distribution.
In July 2013, the Centers for Medicare and Medicaid Services (CMS) announced its proposed rule with regard to payment revisions under the 2014 Physician Fee Schedule (PFS) and Clinical Laboratory Fee Schedule (CLFS). The rule states that the real cost for high complexity testing such as flow cytometry in hospital laboratories can be collected from calculations based on aggregate payments by the CMS to hospitals under bundled care. However, the estimated amounts are lower than the actual costs of this testing when done in both hospitals and independent laboratories. Kalorama estimates that the implementation of the rule will lead to further drastic cuts in laboratory reimbursements. Hospital-based flow cytometry laboratories are consequently sponsored by their parent bodies, while independent laboratories depend on the actual revenues for their survival. In addition, according to this rule, the CMS slashed clinical pathology technical codes up to 75% for common services such as flow cytometry, immunohistochemistry, and fluorescence in situ hybridization. This was because the CMS considers these prices as “misvalued codes on the physician fee schedule.”